Ascentage Pharma Group International
AAPG
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$18.28
▼ -2.42%
P/E
-10.45
Mkt Cap
$1.7B
52-Wk Range
$16.36–$42.48
52-Week Range
$16.36 - $42.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 56.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary kinase inhibitor technology targeting resistant cancer mutations including T315I
- Differentiated apoptosis modulation approach through dual Bcl-2/Bcl-xL inhibition
- Strong IP portfolio with multiple patent-protected drug candidates
- Strategic positioning in high-growth Asian pharmaceutical markets with unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Advancement of HQP1351 and APG-2575 through clinical development stages toward potential approvals
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Weak
-8.7% over 3m
Quality
Excellent
High-growth business (142% revenue growth, 82% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying AAPG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 18, 2026
Reported EPS of -$1.30 vs -$0.22 consensus (-491.0% surprise). Revenue of $44.9M vs $53.6M expected (-16.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-491.0%
Revenue trend · last 8Q
—
+36%
-24%
+477%
+98%
-72%
+113%
+28%
Q4 22
Q2 23
Q4 23
Q2 24
Q4 24
Q2 25
Q4 25
Q2 26
$2.3M
$3.1M
$1.7M
$17.8M
$3.4M
$5.0M
$7.2M
$44.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-270.2%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Jun 10, 2026
vs Industry
How AAPG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related